Natural Strongman Anti-Doping Procedure
1. Policy Purpose and Scope
The purpose of this policy is to maintain the integrity of the sport, ensure fair competition, and protect the health and safety of athletes by preventing the use of performance-enhancing drugs (PEDs) and substances of abuse (SOA). This policy applies to all athletes participating in events organized by Natural Strongman.
Click here to read out Anti-Doping Policy
2. Prohibited Substances and Methods
Natural Strongman maintains its own list of prohibited substances and methods. This list will be reviewed and updated annually and includes categories such as anabolic agents, stimulants, diuretics, and other substances that could enhance performance unfairly.
3. Therapeutic Use Exemptions (TUE)
Athletes with medical conditions requiring the use of prohibited substances or methods must apply for a TUE. The application must include comprehensive medical documentation and will be reviewed by an independent panel to ensure fairness and compliance with medical standards.
4. Testing Procedures
Testing will be conducted both in-competition and out-of-competition. The procedures will include:
Notification: Athletes will be notified of their selection for testing by a Doping Control Officer (DCO).
Sample Collection: Athletes will provide urine and/or hair samples under the supervision of a DCO. The samples will be split into A and B samples for verification purposes.
Chain of Custody: Samples will be securely transported to accredited laboratories for analysis.
5. Results Management
Adverse Analytical Findings: If a sample tests positive, the athlete will be notified and given the opportunity to request the analysis of the B sample, the athlete must pay to have the B sample tested themselves. If the B sample confirms the positive result, the athlete will face potential sanctions.
6. Sanctions
Sanctions for doping violations will include disqualification, suspension, and fines. Repeat offenses will result in harsher penalties.
7. Review and Amendments
This policy will be reviewed annually to incorporate updates from medical and scientific research. Any amendments will be communicated to members in a timely manner.
This policy aims to uphold the values of clean sport and ensure that all competitors have a fair and safe environment to showcase their strength and skills. By adopting these comprehensive measures, Natural Strongman can maintain the integrity of its competitions and the health of its athletes.
Natural Strongman Banned Substance List 2024
ANABOLIC ANDROGENIC STEROIDS (AAS):
• 1-Androstenediol (5ɑ-androst-1-ene-3ß, 17ß-diol) • 1-Androstenedione (5ɑ-androst-1-ene-3, 17-dione) • 1-Androsterone (3ɑ-hydroxy-5a-androst-1- ene-17-one) • 1-Epiandrosterone (3ß-hydroxy-5ɑ-androst1-ene-17-one) • 1-Testosterone (17ß-hydroxy-5ɑ-androst-1- en-3-one) • 4-Androstenediol (androst-4-ene-3ß, 17ß-diol) • 4-Hydroxytestosterone (4,17ß-dihydroxyandrost-4-en-3-one) • 5-Androstenedione (androst-5-ene-3,17-dione) • 7ɑ-hydroxy-DHEA • 7ß-hydroxy-DHEA • 7-Keto-DHEA • 17ɑ-methylepithiostanol (epistane) • 19-Norandrostenediol (estr-4-ene-3,17-diol) • 19-Norandrostenedione (estr-4-ene-3,17-dione) • Androst-4-ene-3,11,17- trione (11-ketoandrostenedione, adrenosterone) • Androstanolone (5ɑ-dihydrotestosterone, 17ß-hydroxy-5ɑ-androstan-3-one) • Androstenediol (androst-5-ene-3ß,17ß-diol) • Androstenedione (androst-4-ene-3,17-dione) • Bolasterone • Boldenone • Boldione (androsta-1,4-diene-3,17-dione) • Calusterone • Clostebol • Danazol ([1,2]oxazolo[4’,5’:2,3]pregna-4-en20-yn-17ɑ-ol) • Dehydrochlormethyltestosterone (4-chloro17ß-hydroxy-17ɑ-methylandrosta-1,4-dien-3- one) • Desoxymethyltestosterone (17ɑ-methyl5ɑ-androst-2-en-17ß-ol and 17ɑ-methyl-5ɑandrost-3-en-17ß-ol) • Drostanolone • Epiandrosterone (3ß-hydroxy-5ɑ-androstan17-one) • Epi-dihydrotestosterone (17ß-hydroxy-5ßandrostan-3-one) • Epitestosterone • Ethylestrenol (19-norpregna-4-en-17ɑ-ol) • Fluoxymesterone • Formebolone • Furazabol (17ɑ-methyl [1,2,5] oxadiazolo[3’,4’:2,3]-5ɑ-androstan-17ß-ol) • Gestrinone
• Mestanolone • Mesterolone • Metandienone (17ß-hydroxy-17ɑmethylandrosta-1,4-dien-3-one) • Metenolone • Methandriol • Methasterone (17ß-hydroxy-2ɑ,17ɑ-dimethyl5ɑ-androstan-3-one) • Methyl-1-testosterone (17ß-hydroxy-17ɑmethyl-5ɑ-androst-1-en-3-one) • Methylclostebol • Methyldienolone (17ß-hydroxy-17ɑmethylestra-4,9-dien-3-one) • Methylnortestosterone (17ß-hydroxy-17ɑmethylestr-4-en-3-one) • Methyltestosterone • Metribolone (methyltrienolone, 17ß-hydroxy17ɑ-methylestra-4,9,11-trien-3-one) • Mibolerone • Nandrolone (19-nortestosterone) • Norboletone • Norclostebol (4-chloro-17ß-ol-estr-4-en-3-one) • Norethandrolone • Oxabolone • Oxandrolone • Oxymesterone • Oxymetholone • Prasterone (dehydroepiandrosterone, DHEA, 3ß-hydroxyandrost-5-en-17-one) • Prostanozol (17ß-[(tetrahydropyran-2-yl)oxy]- 1’H-pyrazolo[3,4:2,3]-5ɑ-androstane) • Quinbolone • Stanozolol • Stenbolone • Testosterone • Tetrahydrogestrinone (17-hydroxy-18ahomo-19-nor-17ɑ-pregna-4,9,11-trien-3-one) • Tibolone • Trenbolone (17ß-hydroxyestr-4,9,11-trien-3- one) Trestolone (7α-methyl-19-nortestosterone)
OTHER ANABOLIC AGENTS:
Clenbuterol, osilodrostat, ractopamine, selective androgen receptor modulators [SARMs, e.g. andarine, enobosarm (ostarine), LGD-4033 (ligandrol), RAD140, S-23 and YK-11], zeranol and zilpaterol.
PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS:
ERYTHROPOIETINS (EPO) AND AGENTS AFFECTING ERYTHROPOIESIS:
Including, but not limited to: 1.1 Erythropoietin receptor agonists, e.g. darbepoetins (dEPO); erythropoietins (EPO); EPO-based constructs [e.g. EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)]; EPO-mimetic agents and their constructs (e.g. CNTO-530, peginesatide). 1.2 Hypoxia-inducible factor (HIF) activating agents, e.g. cobalt; daprodustat (GSK1278863); IOX2; molidustat (BAY 85-3934); roxadustat (FG-4592); vadadustat (AKB-6548); xenon. 1.3 GATA inhibitors, e.g. K-11706. 1.4 Transforming growth factor beta (TGF-ß) signalling inhibitors, e.g. luspatercept; sotatercept. 1.5 Innate repair receptor agonists, e.g. asialo EPO; carbamylated EPO (CEPO).
PEPTIDE HORMONES AND THEIR RELEASING FACTORS:
Chorionic gonadotrophin (CG) and luteinizing hormone (LH) and their releasing factors in males, e.g. buserelin, deslorelin, gonadorelin, goserelin, leuprorelin, nafarelin and triptorelin 2.2 Corticotrophins and their releasing factors, e.g. corticorelin 2.3 Growth hormone (GH), its analogues and fragments including, but not limited to: • growth hormone analogues, e.g. lonapegsomatropin, somapacitan and somatrogon • growth hormone fragments, e.g. AOD-9604 and hGH 176-191 2.4 Growth hormone releasing factors, including, but not limited to: • growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin) • growth hormone secretagogues (GHS) and their mimetics [e.g. lenomorelin (ghrelin), anamorelin, ipamorelin, macimorelin and tabimorelin] • GH-releasing peptides (GHRPs) [e.g. alexamorelin, GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5, GHRP-6, and examorelin (hexarelin)]. BPC157
. GROWTH FACTORS AND GROWTH FACTOR MODULATORS:
Including, but not limited to: • Fibroblast growth factors (FGFs) • Hepatocyte growth factor (HGF) • Insulin-like growth factor 1 (IGF-1) and its analogues • Mechano growth factors (MGFs) • Platelet-derived growth factor (PDGF) • Thymosin-ß4 and its derivatives e.g. TB-500 • Vascular endothelial growth factor (VEGF) and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.
HORMONE AND METABOLIC MODULATORS
AROMATASE INHIBITORS:
• 2-Androstenol (5ɑ-androst-2-en-17-ol) • 2-Androstenone (5ɑ-androst-2-en-17-one) • 3-Androstenol (5ɑ-androst-3-en-17-ol) • 3-Androstenone (5ɑ-androst-3-en-17-one) • 4-Androstene-3,6,17 trione (6-oxo) • Aminoglutethimide • Anastrozole • Androsta-1,4,6-triene-3,17-dione (androstatrienedione) • Androsta-3,5-diene-7,17-dione (arimistane) • Exemestane • Formestane • Letrozole • Testolactone
ANTI-ESTROGENIC SUBSTANCES [ANTI-ESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)]
Bazedoxifene • Clomifene • Cyclofenil • Fulvestrant • Ospemifene • Raloxifene • Tamoxifen • Toremifene
AGENTS PREVENTING ACTIVIN RECEPTOR IIB ACTIVATION
Activin A-neutralizing antibodies • Activin receptor IIB competitors such as: – Decoy activin receptors (e.g. ACE-031) • Anti-activin receptor IIB antibodies (e.g. bimagrumab) • Myostatin inhibitors such as: – Agents reducing or ablating myostatin expression – Myostatin-binding proteins (e.g. follistatin, myostatin propeptide) – Myostatin- or precursor-neutralizing antibodies (e.g. apitegromab, domagrozumab, landogrozumab, stamulumab)
METABOLIC MODULATORS:
Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR, SR9009; and peroxisome proliferator-activated receptor delta (PPARδ) agonists, e.g. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio) phenoxy) acetic acid (GW1516, GW501516) 4.4.2 Insulins and insulin-mimetics 4.4.3 Meldonium 4.4.4 Trimetazidine
DIURETICS AND MASKING AGENTS:
All diuretics and masking agents, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Including, but not limited to: • Desmopressin; probenecid; plasma expanders, e.g. intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol. • Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide; torasemide; triamterene and vaptans, e.g. tolvaptan. and other substances with a similar chemical structure or similar biological effect(s).